• 5 out of 10 patients receiving highest doses of BZDS1901 saw tumour shrinkage of more than 30%
• Tumours became undetectable in 2 out of 10 patients, a highly unusual 20% complete response rate
• Over a quarter of all patients showed ongoing tumour shrinkage, indicating CAR-T persistence

AdAlta's subsidiary AdCella has received further positive clinical results from ongoing investigator-initiated trials of its first-in-class CAR-T therapy, BZDS1901, in advanced mesothelioma. 14 mesothelioma patients have now been treated with the Gen 2 version of BZDS1901, all of whom had previously relapsed or failed to respond to at least one course of chemotherapy or immunotherapy. At the highest doses of Gen 2 BZDS1901 tested to date, 5 out of 10 patients are experiencing tumour shrinkage of more than 30%, representing a 50% overall response rate, more than double current treatment options. Impressively, tumours can no longer be detected by CT imaging in 2 out of 10 patients, representing a highly unusual 20% complete response rate. Over a quarter of all patients have shown ongoing tumour shrinkage, providing evidence of CAR-T persistence. The updated safety protocols have allowed higher doses to be given with manageable toxicities. These positive clinical results continue to support exploration of higher dosing and future studies.

No high-importance, price-sensitive forward-looking financial metrics provided.

Planning is underway for an additional extension cohort of up to five additional patients, subject to agreement with the clinical partner. Additional follow-up data will continue to be collected from existing patients. AdCella remains focused on progressing BZDS1901 toward Western clinical development.